Сравнительный анализ клинических характеристик сирийских женщин с миомой матки и различным индексом массы тела

1. Алали О.М., Чурносов М.И. Полногеномные исследования миомы матки. Акушерство и гинекология. 2023; 7: 28-38.
2. Ponomarenko I., Reshetnikov E., Polonikov A., Verzilina I., Sorokina I., Yermachenko A. et al. Candidate genes for age at menarche are associated with uterine leiomyoma. Front. Genet. 2021; 11: 512940. https://dx.doi.org/10.3389/fgene.2020.512940
3. Алали О.М., Хаддам В.М., Чурносов М.И. Клинические характеристики сирийских женщин с лейомиомой матки. Акушерство и гинекология. 2025; 7: 76-83.
4. Пономаренко И.В., Полоников А.В., Чурносов М.И. Полиморфные локусы гена LHCGR, ассоциированные с развитием миомы матки. Акушерство и гинекология. 2018; 10: 86-91.
5. Qin H., Lin Z., Vásquez E., Luan X., Guo F., Xu L. Association between obesity and the risk of uterine fibroids: a systematic review and meta-analysis. J. Epidemiol. Community Health. 2021; 75: 197-204. https://doi.org/10.1136/jech-2019-213364
6. Maghraby N., El Noweihi A.M., El-Melegy N.T., Mostafa N.A., Abbas A.M., El-Deek H.E. et al. Increased expression of fibroblast activation protein is associated with autophagy dysregulation and oxidative stress in obese women with uterine fibroids. Reprod. Sci. 2021; 29(2): 1-2. https://dx.doi.org/10.1007/s43032-021-00810-0
7. Alali O.M., Churnosov M.I. The etiopathogenesis of uterine leiomyomas: a review. Gynecology. 2023; 25(1): 22-30. https://dx.doi.org/10.26442/20795696.2023.1.201827
8. Пономаренко М.С., Решетников Е.А., Пономаренко И.В., Чурносов М.И. Факторы риска развития миомы матки. Акушерство и гинекология. 2024; 3: 20-7.
9. Sharami S.H., Fallah Arzpeyma S., Shakiba M., Montazeri S., Milani F., Kazemi S. et al. Relationship of uterine fibroids with lipid profile, anthropometric characteristics, subcutaneous and preperitoneal fat thickness. Arch. Iran. Med. 2019; 22(12): 716-21.
10. Pan H., Qin F., Deng F. Clinical value of body mass index and waist-hip ratio in clinicopathological characteristics and prognosis of uterine leiomyomata. Evid. Based Complement. Alternat. Med. 2021; 2021: 8156288. https://dx.doi.org/10.1155/2021/8156288
11. Пономаренко М.С., Решетников Е.А., Пономаренко И.В., Чурносов М.И. Этиопатогенетические механизмы развития миомы матки. Акушерство и гинекология. 2024; 1: 34-41.
12. Gürbüz T., Yardımcı O., Udum S., Günay T. The relationship between body mass index and clinical complications among patients undergoing myomectomy. J. Surg. Med. 2020; 4(11): 1027-30. https://dx.doi.org/10.28982/josam.805122
13. Lee J.E., Song S., Cho E., Jang H.J., Jung H., Lee H.Y. et al. Weight change and risk of uterine leiomyomas: Korea Nurses’ Health Study. Cur. Med. Res. Opin. 2018; 34(11): 1913-9. https://dx.doi.org/10.1080/03007995.2018.1462783
14. Haan Y.C., Diemer F.S., Van der Woude L., Van Montfrans G.A., Oehlers G.P., Brewster L.M. The risk of hypertension and cardiovascular disease in women with uterine fibroids. J Clin Hypertens (Greenwich). 2018; 20(4): 718-26. https://dx.doi.org/10.1111/jch.13253
15. Пономаренко И.В., Чурносов М.И. Современные представления об этиопатогенезе и факторах риска лейомиомы матки. Акушерство и гинекология. 2018; 8: 27-32.
16. Muawad R., Dabbagh R., Sabr Y. Association of health and lifestyle factors with uterine fibroids among Saudi women: a case–control study. J. Taibah Univ. Med. Sci. 2022; 17(6): 1039-46. https://dx.doi.org/10.1016/j.jtumed.2022.06.005
17. Keizer A.L., Semmler A., Kok H.S., van Kesteren P.J., Huirne J.A., Hehenkamp W.J. Modifiable prognostic factors in uterine fibroid development: a systematic review of literature. J. Obstet. Gynaecol. 2024; 44(1): 2288225. https://dx.doi.org/10.1080/01443615.2023.2288225
18. Donnez J., Dolmans M.M. Uterine fibroid management: from the present to the future. Hum. Reprod. Update. 2016; 22(6): 665-86. https://dx.doi.org/10.1093/humupd/dmw023
19. Wise L.A., Laughlin-Tommaso S.K. Epidemiology of uterine fibroids – from menarche to menopause. Clin. Obstet. Gynecol. 2016; 59(1): 2-24. https://dx.doi.org/10.1097/GRF.0000000000000164
20. Ponomarenko M.S., Reshetnikov E.A., Churnosova M.M., Reshetnikova Y.N., Churnosov V.I., Ponomarenko I.V. Comorbidity and syntropy of benign proliferative diseases of the female reproductive system: non-genetic, genetic, and epigenetic factors (review). Research Results in Biomedicine. 2023; 9(4): 544-56. https://dx.doi.org/10.18413/2658- 6533-2023-9-4-0-9
21. Stewart E.A., Cookson C.L., Gandolfo R.A., Schulze‐Rath R. Epidemiology of uterine fibroids: a systematic review. BJOG. 2017; 124(10): 1501-12. https://dx.doi.org/10.1111/1471-0528.14640
22. Nwonuma C., Irokanulo E., Bamgboye F., Akinduko A., Okeniyi F., Eigbe C. Uterine fibroid: risk factors and therapeutic interventions. In: International conference on science, engineering and business for driving sustainable development goals (SEB4SDG), 2024 Apr. 2-4. Omu-aran;2024: 1-10.
23. Shabahat Ahmed A., Kiran Sharif M.A. Prevalence and clinical characteristics of uterine fibroids in women of reproductive age in district hyderabad. The Research of Medical Science Review. 2025; 3(1): 635-47.
24. Pavone D., Clemenza S., Sorbi F., Fambrini M., Petraglia F. Epidemiology and risk factors of uterine fibroids. Best Pract. Res. Clin. Obstet. Gynaecol. 2018; 46: 3-11. https://dx.doi.org/10.1016/J.BPOBGYN.2017.09.004
25. Zapata L.B., Whiteman M.K., Tepper N.K., Jamieson D.J., Marchbanks P.A., Curtis K.M. Intrauterine device use among women with uterine fibroids: a systematic review. Contraception. 2010; 82(1): 41-55. https://dx.doi.org/10.1016/j.contraception.2010.02.011
26. Пономарева Т.А. Генетические варианты глобулина, связывающего половые гормоны, и гормональный профиль больных генитальным эндометриозом. Научные результаты биомедицинских исследований. 2025; 11(1): 75-90.
27. Ponomarenko M.S. The relationship between the genetic determinants of SHBG and the hormonal profile of patients with uterine fibroids. Research Results in Biomedicine. 2025; 11(4): 628-42. https://dx.doi.org/10.18413/2658-6533-2025-11-4-0-3
28. Alsudairi H.N., Alrasheed A.T., Dvornyk V. Estrogens and uterine fibroids: an integrated view. Research Results in Biomedicine. 2021; 7(2): 156-63. https://dx.doi.org/10.18413/2658-6533-2021-7-2-0-6
29. Чурносов В.И. Ассоциации полиморфных локусов генов-кандидатов с уровнем половых гормонов у больных гиперплазией эндометрия. Научные результаты биомедицинских исследований. 2025;11(2):243-262.
30. Harmon Q.E., Patchel S., Denslow S., Wegienka G., Baird D.D. Body mass index and uterine fibroid development: a prospective study. The Journal of Clinical Endocrinology & Metabolism. 2024; 109(11): e2016-23. https://dx.doi.org/10.1210/clinem/dgae036
31. Bray M.J., Torstenson E.S., Jones S.H., Edwards T.L., Edwards D.R. Evaluating risk factors for differences in fibroid size and number using a large electronic health record population. Maturitas. 2018; 114: 9-13. https://dx.doi.org/10.1016/j.maturitas.2018.05.003
32. Ponomarenko M., Reshetnikov E., Churnosova M., Aristova I., Abramova M., Novakov V. et al. Genetic variants linked with the concentration of sex hormone-binding globulin correlate with uterine fibroid risk. Life (Basel). 2025; 15(7): 1150. https://dx.doi.org/10.3390/life15071150

Поступила 18.11.2025

Принята в печать 28.04.2026